Xylem was upgraded at DA Davidson to neutral from underperform. $34 price target. Company boosted its guidance and announced surprise growth, DA Davidson said.

Stock Comments/EPS Changes

Acadia Healthcare ( ACHC) numbers, price target were raised at Jefferies. Shares are now seen reaching $47. Strong top-line growth and upside in margin expansion, Jefferies said. Estimates lifted into next year. Buy rating.

Actavis ( ACT) estimates, price target were increased at Jefferies. Company expects double-digit organic growth after in-line third-quarter results. $168 price target and hold rating.

Archer-Daniels-Midland ( ADM) numbers were increased at BMO Capital. Estimates were boosted through 2014. Company is seeing higher divisional profits and a higher LIFO benefit, BMO Capital said. Market perform rating and new $42 price target.

Aetna ( AET) estimates, price target were lowered at BMO Capital. Estimates were cut through 2014. Company reduced its guidance, BMO Capital said. Outperform rating and new $70 price target.

Ameriprise ( AMP) estimates, price target were boosted at Credit Suisse. Shares are now seen reaching $100. Estimates were also increased, given better asset management growth, Credit Suisse said. Neutral rating.

Cummins ( CMI) estimates, price target were reduced at BMO Capital. Shares are now seen reaching $144. Estimates were also cut, given the company's new guidance, BMO Capital said. Outperform rating.

Dana estimates, price target are lowered at Jefferies. Weakness in commercial vehicles, Jefferies said. $23 price target and buy rating.

Gilead ( GILD) estimates, price target were increased at Credit Suisse. Estimates were raised through 2015. Company is seeing higher sales and keeping a tight lid on costs, Credit Suisse said. Outperform rating and new $80 price target.

Gilead Sciences ( GILD) price target was raised at J.P. Morgan to $85. Strong third-quarter with upside in HIV-related sales, J.P. Morgan said. Overweight rating.

L-3 Communications ( LLL) estimates, price target were raised at Credit Suisse. Price target was increased to $97. Estimates were also increased, as the company is realizing higher margins.

LinkedIn ( LNKD) estimates, price target were boosted at Credit Suisse. Shares are now seen reaching $288. Estimates were also increased, given the company's new guidance. Outperform rating.

Questcor Pharmaceuticals ( QCOR) estimates, price target were increased at Jefferies. QCOR raised its numbers, said Jefferies. Very robust Acthar growth in rheumatology, Jefferies also said. $76 price target and buy rating.

Titan International ( TWI) estimates, price target were lowered at Jefferies. TWI decreased its numbers into next year. Uncertainty reflecting commodity end markets and company execution, Jefferies said. $16 price target and Hold rating.

Valero ( VLO) estimates, price target were raised at Credit Suisse. Shares are now seen reaching $40. Crude spreads have widened, Credit Suisse said. Neutral rating.

Vertex ( VRTX) estimates, price target were cut at Credit Suisse. Shares are now seen reaching $78. Estimates were also reduced, given lower Incivek sales, Credit Suisse said. Neutral rating.

Western Union ( WU) numbers were cut at Sterne Agee. Shares are now seen reaching $20. Estimates were also reduced, given the company's new guidance, Sterne Agee said. Buy rating.

>To submit a news tip, email: tips@thestreet.com.

Follow TheStreet on Twitter and become a fan on Facebook.
This article was written by a staff member of TheStreet.

If you liked this article you might like

Fed, Toys 'R' Us, Equifax and Hurricane Maria - 5 Things You Must Know

It's Decision Time for the Fed in the Week Ahead

Fight Off Complacency: Cramer's 'Mad Money' Recap (Fri 9/15/17)

Analysts Wrong on iPhone; Retail Not Going Away: Best of Cramer